SEARCH RESULT

Total Matching Records found : 382

The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri

-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...

More »

The Cost of Drugs: Beyond the Supreme Court Order -Sanjay Nagral

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...

More »

Rajasthan govt to give free cancer drugs -Syed Intishab Ali

-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by Novartis at...

More »

Landmark verdict -V Venkatesan

-Frontline   The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...

More »

Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close